Study of Safety and Tolerability of Intravenous ANZ-100 in Adults with Carcinoma and Liver Metastases

*Single IV dose of ANZ-100

Antibiotics x 10d

5 day hospitalization

<table>
<thead>
<tr>
<th>-14</th>
<th>-7</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>8</th>
<th>16</th>
<th>29</th>
</tr>
</thead>
</table>

Days

Eligibility Criteria: treatment-refractory carcinoma and hepatic metastases, > 18 years old, with a life expectancy of >12 weeks, an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, adequate organ function, no ongoing systemic infections, history of brain metastases, history of autoimmune disease or immunosuppression

Dose Levels: $1 \times 10^6$ cfu, $3 \times 10^7$ cfu, $3 \times 10^8$ cfu

Treatment Plan: Single IV dose of ANZ-100 given on day 1 followed by a 5 day hospitalization and a 29 day observation period. Antibiotics 7 days after the dose.